Five years after Kymriah: Ensuring the next cell and gene therapies reach patients

Five years ago today, the Food and Drug Administration issued a landmark approval for Kymriah, the first gene therapy available in the United States. Cell and gene therapy products can transform how certain diseases are treated, offering life-extending and potentially curative benefits for patients living with life-threatening or debilitating diseases. Propelled by significant research and development investments and scientific advances, the cell and gene therapy market has since experienced tremendous growth. Regulatory agencies around the world have approved a number of cell and gene therapy products — including eight new therapies in the United States — that target diseases with high unmet needs, ranging from cancer to retinal diseases.

For the full article, please visit STAT News.